This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ecolab's (ECL) Q1 Earnings in Line, Revenues Beat Estimates
by Zacks Equity Research
Ecolab's (ECL) robust performance across all of its segments drives its Q1 sales despite business challenges.
Quidel (QDEL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel's (QDEL) first-quarter results are likely to reflect continued strength across its SARS-related products.
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
QGEN or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
QGEN vs. ILMN: Which Stock Is the Better Value Option?
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN's (QGEN) recent expansion in test menu and strategic collaborations.
QIAGEN (QGEN) QuantiFeron Hits New Sales Landmark in TB Testing
by Zacks Equity Research
According to QIAGEN (QGEN), QuantiFERON is different from other IGRA tests based on its efficient workflow.
Allogene Therapeutics (ALLO) Soars 8.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Illumina (ILMN) Debuts TSO Comprehensive Test in Europe
by Zacks Equity Research
Illumina's (ILMN) novel CE-marked IVD kit for comprehensive genomic profiling will enable clinicians to match cancer patients with available therapies.
Illumina (ILMN) Invests in Seven Additional Genomics Startups
by Zacks Equity Research
Illumina's (ILMN) investment in seven new genomics companies is intended to advance breakthrough therapeutics, diagnostics, DNA storage, mental wellness and sustainable foods applications.
Why Is Qiagen (QGEN) Down 11.3% Since Last Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is QIAGEN (QGEN) a Great Stock for Value Investors?
by Zacks Equity Research
Is QIAGEN (QGEN) a great pick from the value investor's perspective right now? Read on to know more.
QIAGEN (QGEN) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
High demand for COVID-19 test products and improving trends in the non-COVID portfolio drove QIAGEN's (QGEN) fourth-quarter revenues.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN's (QGEN) progress with testing solutions and strategic collaborations.
QIAGEN (QGEN) to Boost Testing Capacity With Liquid-Based Kit
by Zacks Equity Research
QIAGEN's (QGEN) artus SARS-CoV-2 Prep&Amp UM is faster than standard processes and can spot the virus more reliably, including the new Omicron variant.
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific Inc., QIAGEN N.V. Quest Diagnostics and Quidel Corp.
by Zacks Equity Research
Thermo Fisher Scientific Inc., QIAGEN N.V. Quest Diagnostics,and Quidel Corp. are highlighted in this analyst blog.
3 Diagnostics Stocks in Focus Amid the Omicron Outbreak
by Riya Anand
Stocks like Thermo Fisher (TMO), QIAGEN (QGEN) and Quidel (QDEL) are expected to gain from increasing testing demand.
QIAGEN (QGEN), Denovo to Develop CDx Test for Lymphoid Cancer
by Zacks Equity Research
QIAGEN (QGEN) will develop a diagnostic assay that can identify the Denovo Genomic Marker 1 in patients with lymphoid cancer.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN (QGEN) on strong third-quarter results and raised 2021 guidance.
QIAGEN (QGEN) Gets CE Mark for QuantiFERON SARS-CoV-2 Assay
by Zacks Equity Research
QIAGEN's (QGEN) QuantiFERON SARS-CoV-2 assay enables a comprehensive assessment of immunity developed by COVID-19 vaccines.
Qiagen (QGEN) Down 1.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN (QGEN), DiaSorin to Broaden Access to Latent TB Testing
by Zacks Equity Research
QIAGEN (QGEN) and DiaSorin gained FDA approval for their jointly-created LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin's automated LIAISON XS platform.
QIAGEN (QGEN) Q3 Earnings Surpass Estimates, 2021 View Up
by Zacks Equity Research
QIAGEN (QGEN) exited third-quarter 2021 with better-than-expected results on strength in the two major customer classes driving the top line.
Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 9.43% and 9.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.